Legal & General Group Plc purchased a new stake in Biohaven Ltd. (NYSE:BHVN – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 94,255 shares of the company’s stock, valued at approximately $1,403,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC raised its position in shares of Biohaven by 1,145.9% during the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the last quarter. BlackRock Inc. bought a new stake in Biohaven in the second quarter valued at approximately $196,574,000. Suvretta Capital Management LLC boosted its holdings in Biohaven by 83.0% in the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after acquiring an additional 4,666,666 shares during the last quarter. Stifel Financial Corp increased its position in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock valued at $112,221,000 after purchasing an additional 3,328,506 shares during the period. Finally, Infinitum Asset Management LLC raised its holdings in Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after purchasing an additional 4,550,000 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.
Biohaven Price Performance
Biohaven stock opened at $15.69 on Monday. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The firm’s fifty day moving average is $14.86 and its 200 day moving average is $12.02. The company has a market capitalization of $2.37 billion, a PE ratio of -3.38 and a beta of 1.28.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on BHVN. Bank of America restated an “underperform” rating and issued a $11.00 price target (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Needham & Company LLC set a $11.00 target price on shares of Biohaven in a research note on Monday, June 29th. Royal Bank Of Canada upped their price target on shares of Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $30.00 price objective on shares of Biohaven in a research note on Wednesday, August 26th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.94.
Get Our Latest Stock Report on BHVN
Biohaven Profile
Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.
The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.
Featured Stories
- Five stocks we like better than Biohaven
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd. (NYSE:BHVN – Free Report).
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.
